期刊
CANCER RESEARCH
卷 74, 期 23, 页码 7125-7136出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-14-1017
关键词
-
类别
资金
- German Research Foundation (DFG) [AZ.96/1-1]
- Deutsche Krebshilfe [109373]
- DFG [SE.676/10-1]
- Emmy Noether Fellowship from the DFG
- [R01 CA172546]
- [R01 CA155226]
The kinase PRKD2 (protein kinase D) is a crucial regulator of tumor cell-endothelial cell communication in gastrointestinal tumors and glioblastomas, but its mechanistic contributions to malignant development are not understood. Here, we report that the oncogenic chaperone HSP90 binds to and stabilizes PRKD2 in human cancer cells. Pharmacologic inhibition of HSP90 with structurally divergent small molecules currently in clinical development triggered proteasome-dependent degradation of PRKD2, augmenting apoptosis in human cancer cells of various tissue origins. Conversely, ectopic expression of PRKD2 protected cancer cells from the apoptotic effects of HSP90 abrogation, restoring blood vessel formation in two preclinical models of solid tumors. Mechanistic studies revealed that PRKD2 is essential for hypoxia-induced accumulation of hypoxia-inducible factor-1 alpha (HIF1 alpha) and activation of NF-kappa B in tumor cells. Notably, ectopic expression of PRKD2 was able to partially restore HIF1 alpha and secreted VEGF-A levels in hypoxic cancer cells treated with HSP90 inhibitors. Taken together, our findings indicate that signals from hypoxia and HSP90 pathways are interconnected and funneled by PRKD2 into the NF-kappa B/VEGF-A signaling axis to promote tumor angiogenesis and tumor growth. (C)2014 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据